AstraZeneca’s durvalumab (IMFINZI) has been granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of patients with muscle-invasive bladder cancer (MIBC). This decision is based on data from the phase 3 NIAGARA trial, which demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) and overall survival (OS) for patients receiving perioperative durvalumab in combination with standard therapies. FDA approval would make durvalumab the only perioperative immunotherapy regimen available in the curative-intent setting. ...
Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Robotic cystectomy after neoadjuvant immunotherapy shows higher severe complication rates than surgery alone.
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
IMvigor011 compared the efficacy of atezolizumab with placebo in patients with HR MIBC who remained ctDNA+ post-cystectomy.
The study examined the prognostic value of ctDNA as a biomarker in patients with muscle-invasive bladder cancer.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Section Editor
Brad McGregor, MDGenitourinary Medical Oncologist | Dana-Farber Cancer Institute
Advertisement
Get the latest bladder cancer research straight to your inbox.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.